Investigator-Initiated Clinical Trial AgreementInvestigator-Initiated Clinical Trial Agreement • March 22nd, 2022
This Investigator-Initiated Clinical Trial Agreement (“Agreement”) is made as of this {DAY} day of {MONTH}, {YEAR} (the “Effective Date”) by and between the Board of Regents of the University of Wisconsin System on behalf of the University of Wisconsin-Madison, a public higher educational institution with an address at 21 N. Park Street Suite 6301, Madison, WI 53715 (“Institution”) and {COMPANY NAME}, a corporation having its principal place of business at {COMPANY ADDRESS} (“Company”). Company and Institution are herein referred to collectively as “Parties.” Individually, each of Institution and Company is a “Party.”
INVESTIGATOR INITIATED CLINICAL TRIAL AGREEMENTInvestigator Initiated Clinical Trial Agreement • October 21st, 2019 • Kazia Therapeutics LTD • Pharmaceutical preparations • Massachusetts
This Investigator Initiated Clinical Trial Agreement (“Agreement”) is made as of the _I7* day of October. 20LS (“Effective Date”) between Kazia Therapeutics Ltd (ACN 063 259 754) a company incorporated in Australia with a principal place of business at 1.24, 300 Barangaroo Avenue, Sydney, NSW 2000, Australia (“Company”), and Dana-Farber/Partners Cancer Care, Inc., a collaboration among Dana-Farber Cancer Institute, The Brigham and Women’s Hospital, Inc. and The General Hospital Corporation, d/b/a Massachusetts General Hospital, a not-for-profit tax-exempt corporation organized under the laws of the Commonwealth of Massachusetts with its principal place of business at 44 Binney Street, Boston, MA 02115 (“Institution”) each referred to herein individually as a “Party” and collectively as the “Parties”.
Investigator Initiated Clinical Trial AgreementInvestigator Initiated Clinical Trial Agreement • June 22nd, 2017
THIS AGREEMENT is entered into effective as of (the “Effective Date”) by and between Regents of the University of Minnesota (the "University"), a public educational institution and a Minnesota constitutional corporation, and (the “Sponsor”), a . This Agreement is entered into by the University through its Office of Sponsored Projects Administration.
INVESTIGATOR INITIATED CLINICAL TRIAL AGREEMENTInvestigator Initiated Clinical Trial Agreement • October 22nd, 2020 • Kazia Therapeutics LTD • Pharmaceutical preparations • Massachusetts
This Investigator Initiated Clinical Trial Agreement (“Agreement”) is made as of the 18th September 2020 (“Effective Date”) between Kazia Therapeutics Limited (ACN 063 259 754) a company incorporated in Australia with a principal place of business at L24, 300 Barangaroo Avenue, Sydney, NSW 2000, Australia (“Company”), and Dana-Farber/Partners Cancer Care, Inc., a collaboration among Dana-Farber Cancer Institute, The Brigham and Women’s Hospital, Inc. and The General Hospital Corporation, d/b/a Massachusetts General Hospital, a not-for-profit tax-exempt corporation organized under the laws of the Commonwealth of Massachusetts with its principal place of business at 450 Brookline Ave., Boston, MA 02215 (“Institution”) each referred to herein individually as a “Party” and collectively as the “Parties”.
Investigator-Initiated Clinical Trial Agreement Collaboration AgreementInvestigator-Initiated Clinical Trial Agreement • September 3rd, 2023
[Insert name of Institution Investigator] shall be responsible for the performance of the Trial on behalf of Institution
Investigator-Initiated Clinical TRIAL agreementInvestigator-Initiated Clinical Trial Agreement • April 5th, 2020
Regarding the trial entitled: “Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia – the COVID STEROID Trial, (hereinafter the “Trial”)
Investigator initiated clinical trial agreement templateInvestigator Initiated Clinical Trial Agreement • January 16th, 2021
Information about cancer prevention, early detection and supportive care clinical trials, including Phase I, II and III agent and action trials and clinical trial management, actively enrolling, ongoing and completed clinical trials. If you decide to seek a clinical trial, it is worth knowing some details about cancer diagnosis and comparing these details with the eligibility criteria of any trial that interests you. Eligibility criteria are requirements that must be met in order to participate in a clinical trial. Examples of eligibility criteria include: Having a specific type or stage of cancer Having received (or not receiving) a specific type of treatment in the past Having certain genetic changes to your tumor To help you collect details about cancer, health status with a medical history in a given age group To help you collect details about cancer, complete as much of the Cancer Details Checklist as possible. See the form during the search for a clinical trial. If you need help
INVESTIGATOR INITIATED-CLINICAL TRIAL AGREEMENTInvestigator Initiated Clinical Trial Agreement • May 26th, 2021 • XORTX Therapeutics Inc. • Pharmaceutical preparations • New York
This Investigator-Initiated Clinical Trial Agreement ("Agreement") effective this 3rd day of August, 2020, (the "Effective Date") is by and between ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, a non-profit corporation, having its principal offices at One Gustave L. Levy Place, New York, NY 10029 ("INSTITUTION") and XORTXTherapeutics ("COMPANY"), a Canadian corporation, having its principal offices at Suite 4000, 421-7th Avenue Calgary, Alberta, Canada. INSTITUTION's faculty employee Steven Coca, M.D. ("PRINCIPAL INVESTIGATOR") shall be the Sponsor-Investigator under this Agreement, and shall conduct this Study as an employee of lnstitution and not as a party to this Agreement.
